Artículo de revista
Socioeconomic, clinical, and molecular features of breast cancer influence overall survival of Latin American women
Fecha
2022Registro en:
Frontiers in Oncology March 2022 Volume 12 Article 845527
10.3389/fonc.2022.845527
Autor
Almeida, Liz María de
Cortés, Sandra
Vilensky, Marta
Valenzuela, Olivia
Cortés Sanabria, Laura
Souza, Mirian de
Barbeito, Rafael Alonso
Abdelhay, Eliana
Artagaveytia, Nora
Daneri Navarro, Adrian
Llera, Andrea S.
Müller, Bettina
Podhajcer, Osvaldo L.
Velázquez, Carlos
Alcoba, Elsa
Alonso, Isabel
Bravo, Alicia I.
Camejo, Natalia
Carraro, Dirce Maria
Castro, Mónica
Cataldi, Sandra
Cayota, Alfonso
Cerda Villablanca, Mauricio David
Colombo Flores, Alicia Angelina
Crocamo, Susanne
Toro Arreola, Alicia del
Delgadillo Cristerna, Raúl
Delgado, Lucia
Breitenbach, Marisa Dreyer
Fernández, Elmer
Fernández, Jorge
Fernández, Wanda
Franco Topete, Ramón A
Gaete, Fancy
Gómez, Jorge
González Ramírez, Leivy P.
Guerrero, Marisol
Gutiérrez Rubio, Susan A.
Jalfin, Beatriz
López Vázquez, Alejandra
Loria, Dora
Míguez, Silvia
Morán Mendoza, Andres de J.
Morgan Villela, Gilberto
Mussetti, Carina
Nagai, Maria Aparecida
Oceguera Villanueva, Antonio
Reis, Rui M.
Retamales, Javier
Rodríguez, Robinson
Rosales, Cristina
Salas González, Efraín
Segovia, Laura
Sendoya, Juan M.
Silva García, Aída A.
Viña, Stella
Zagame, Livia
Jones, Beth
Szklo, Moysés
Institución
Resumen
Molecular profile of breast cancer in Latin-American women was studied in five countries: Argentina, Brazil, Chile, Mexico, and Uruguay. Data about socioeconomic characteristics, risk factors, prognostic factors, and molecular subtypes were described, and the 60-month overall cumulative survival probabilities (OS) were estimated. From 2011 to 2013, 1,300 eligible Latin-American women 18 years or older, with a diagnosis of breast cancer in clinical stage II or III, and performance status not less than or equal to 1 were invited to participate in a prospective cohort study. Face-to-face interviews were conducted, and clinical and outcome data, including death, were extracted from medical records. Unadjusted associations were evaluated by Chi-squared and Fisher's exact tests and the OS by Kaplan-Meier method. Log-rank test was used to determine differences between cumulative probability curves. Multivariable adjustment was carried out by entering potential confounders in the Cox regression model. The OS at 60 months was 83.9%. Multivariable-adjusted death hazard differences were found for women living in Argentina (2.27), Chile (1.95), and Uruguay (2.42) compared with Mexican women, for older (>= 60 years) (1.84) compared with younger (<= 40 years) women, for basal-like subtype (5.8), luminal B (2.43), and HER2-enriched (2.52) compared with luminal A subtype, and for tumor clinical stages IIB (1.91), IIIA (3.54), and IIIB (3.94) compared with stage IIA women. OS was associated with country of residence, PAM50 intrinsic subtype, age, and tumor stage at diagnosis. While the latter is known to be influenced by access to care, including cancer screening, timely diagnosis and treatment, including access to more effective treatment protocols, it may also influence epigenetic changes that, potentially, impact molecular subtypes. Data derived from heretofore understudied populations with unique geographic ancestry and sociocultural experiences are critical to furthering our understanding of this complexity.